The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the ...

The stock's fall snapped a two-day winning streak.

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Citi analyst Joanne Wuensch maintained a Buy rating on Dexcom (DXCM – Research Report) today. The company’s shares closed yesterday at ...

CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Dexcom (DXCM – Research Report), with a price target of ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

Dexcom has a well-established record of introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive slice ...